NetworkNewsBreaks – EVIO, Inc. (EVIO) Announces
Post# of 2022
(Total Views: 179)
Posted On: 05/24/2018 5:46:02 PM
NetworkNewsBreaks – EVIO, Inc. (EVIO) Announces Launch of EVIO Biosciences Division
EVIO, Inc. (OTCQB: EVIO), a leading provider of cannabis testing and scientific research for the regulated cannabis industry, this morning announced the launch of its EVIO Biosciences Division. Per the update, the new division, which will be led by Dr. Anthony Smith, chief science officer of EVIO, will allow the company to leverage its scientific and human capital expertise to focus on the development of intellectual property and research. The division’s goals encompass emerging health benefits and advanced delivery modes for cannabinoids and cannabis products targeting the human endocannabinoid system. “We are expanding the life sciences part of the company to focus on the need for bioscience applications in cannabis, in addition to analytical testing services,” Smith stated in the news release. “We are focusing on scientific research to support biotechnology and IP development for advanced formulation, manufacturing and delivery processes… The real benefit will be leveraging our R&D in partnership with medical and healthcare providers to bring solutions to real world health problems.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
EVIO, Inc. (OTCQB: EVIO), a leading provider of cannabis testing and scientific research for the regulated cannabis industry, this morning announced the launch of its EVIO Biosciences Division. Per the update, the new division, which will be led by Dr. Anthony Smith, chief science officer of EVIO, will allow the company to leverage its scientific and human capital expertise to focus on the development of intellectual property and research. The division’s goals encompass emerging health benefits and advanced delivery modes for cannabinoids and cannabis products targeting the human endocannabinoid system. “We are expanding the life sciences part of the company to focus on the need for bioscience applications in cannabis, in addition to analytical testing services,” Smith stated in the news release. “We are focusing on scientific research to support biotechnology and IP development for advanced formulation, manufacturing and delivery processes… The real benefit will be leveraging our R&D in partnership with medical and healthcare providers to bring solutions to real world health problems.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)